Upsylon
Total Payments
$312,484
Transactions
1,375
Doctors
881
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $48,178 | 483 | 350 |
| 2023 | $193,714 | 531 | 408 |
| 2022 | $70,449 | 360 | 251 |
| 2020 | $143.62 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $123,344 | 3 | 39.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110,534 | 80 | 35.4% |
| Food and Beverage | $66,952 | 1,255 | 21.4% |
| Travel and Lodging | $9,199 | 35 | 2.9% |
| Consulting Fee | $2,250 | 1 | 0.7% |
| Education | $205.24 | 1 | 0.1% |
Payments by Type
General
$189,140
1,372 transactions
Research
$123,344
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Permanent versus delayed absorbable monofilament suture for vaginal graft attachment during minimally invasive total hysterectomy and sacrocolpopexy A Randomized Clinical Trial PART II Extension to ISROTH40019 | Boston Scientific Corporation | $123,344 | 0 |
Top Doctors Receiving Payments for Upsylon — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , DO | Urogynecology and Reconstructive Pelvic Surgery | Fresno, CA | $233.61 | 6 |
| , DO | Urogynecology and Reconstructive Pelvic Surgery | Fresno, CA | $233.60 | 6 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Boston, MA | $232.83 | 2 |
| , MD | Internal Medicine | East Islip, NY | $219.75 | 1 |
| , M.D | Gynecology | Franklin, TN | $219.30 | 5 |
| , M.D | Obstetrics & Gynecology | King Of Prussia, PA | $216.53 | 3 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | York, PA | $214.61 | 3 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Chula Vista, CA | $207.43 | 1 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | San Diego, CA | $207.43 | 1 |
| Nishita Patel | Student in an Organized Health Care Education/Training Program | Washington, DC | $207.41 | 2 |
| , MD | Urology | Stuart, FL | $205.24 | 1 |
| , M.D | Obstetrics & Gynecology | Chattanooga, TN | $203.57 | 5 |
| , M.D | Urology | Jasper, AL | $195.25 | 5 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Macon, GA | $195.23 | 5 |
| , MD | General Practice | New Haven, CT | $190.72 | 2 |
| Moiuri Siddique | Student in an Organized Health Care Education/Training Program | Washington, DC | $185.85 | 2 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Washington, DC | $181.54 | 2 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Boston, MA | $174.77 | 3 |
| , MD | Urogynecology and Reconstructive Pelvic Surgery | Birmingham, AL | $168.84 | 2 |
| James Ross | Obstetrics & Gynecology | Cleveland, OH | $167.04 | 3 |
| , MD | Obstetrics & Gynecology | Gainesville, GA | $167.02 | 2 |
| , MD | Obstetrics & Gynecology | Chicago, IL | $165.79 | 2 |
| , M.D | Urogynecology and Reconstructive Pelvic Surgery | Chicago, IL | $165.79 | 2 |
| , MD | Obstetrics & Gynecology | Annapolis, MD | $163.79 | 3 |
| , M.D | Obstetrics & Gynecology | Annapolis, MD | $163.78 | 3 |
Ad
Manufacturing Companies
- Boston Scientific Corporation $306,964
- BOSTON SCIENTIFIC CORPORATION $5,520
Product Information
- Type Device
- Total Payments $312,484
- Total Doctors 881
- Transactions 1,375
About Upsylon
Upsylon is a device associated with $312,484 in payments to 881 healthcare providers, recorded across 1,375 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2020 to 2024. In 2024, $48,178 was paid across 483 transactions to 350 doctors.
The most common payment nature for Upsylon is "Unspecified" ($123,344, 39.5% of total).
Upsylon is associated with 1 research study, including "Permanent versus delayed absorbable monofilament suture for vaginal graft attachment during minimally invasive total hysterectomy and sacrocolpopexy A Randomized Clinical Trial PART II Extension to ISROTH40019" ($123,344).